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ABSTRACT
Persistence is an important component of therapeutic success, which depends on a variety of factors.
Persistence measured under optimal conditions during clinical trials does not necessarily coincide with
persistence observed in the real-world settings. The aim of the present study was to compare persistence
rate of TNF-alpha inhibitors and interleukin 12/23 inhibitor in all psoriasis patients in Hungary, as well as
to analyze the predictors of persistence. Data collected from 1263 patients over a period of 46months
were subjected to a retrospective analysis. Drug survival rate has been calculated according to
Kaplan–Meier analysis and Cox regression was used to study the predictors. The overall persistence rate
for the four biologicals exceeded 60% after 3 years. The persistence rate of ustekinumab at 3 years was
67.83%, which was superior compared to that of the TNF-alpha inhibitors, where the mean persistence
rate was shown to be 50.76% (p< .05). Male patients showed significantly higher persistence than females
(HR¼ .76, p< .05CI: 0.63, 0.92). Age, therapy-naïve status and use of concomitant MTX did not have
significant effect on drug survival. Persistence rate of ustekinumab was significantly higher than that of
TNF-alpha inhibitors, and among predictors, only male gender influenced persistence significantly.
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Introduction
Psoriasis is a common, chronic, immune-mediated skin disease. The
disease and the comorbidities that frequently develop during its
course not only impact the quality of life negatively, but also wor-
sen life expectancy (1,2). Epidemiological studies have shown that
psoriasis patients have shorter life expectancy, particularly those
who develop cardiovascular comorbidities (1). Even though the dis-
ease is currently not curable, there are a number of therapeutic
options which ensure a symptom-free status, although requires a
long term, often lifelong treatment (3,4). Optimal drug survival is
fundamental in the management of psoriasis and comorbidities (5).
Drug survival, that is, persistence, is a comprehensive measure
of therapeutic success, which depends on a variety of factors,
including efficacy, safety, tolerability and patient satisfaction (5).
Suboptimal persistence is a common and complex problem among
patients with chronic diseases, including psoriasis (6–8). Frequent
switches between therapies and clinical research aiming to develop
new therapeutic options to address persistence issues both confirm
this (6). An important breakthrough was the development of bio-
logical therapies, which became available for the treatment of mod-
erate to severe psoriasis. Biological therapies that are now widely
available for psoriasis patients and include the TNF-a inhibitor adali-
mumab, infliximab, etanercept, the IL-12/23 inhibitor ustekinumab,
as well as the IL-17 inhibitor secukinumab and ixekizumab.
Drug survival rate of biologicals seems to be better compared
to local and conventional systemic therapies (9). Persistence meas-
ured under optimal (standardized) conditions in prescreened,
highly motivated patient populations, using tight protocols and
independent investigators during clinical trials does not necessar-
ily coincide with the drug survival of therapies prescribed in the
real-world settings (10,11). There are studies on the short-term
persistence of biological therapies used in psoriasis; however, very
limited comparative evidence is available on the long-term persist-
ence of biological therapies used in the real-world settings (12).
The objectives of this study were to analyze the characteristics of
all psoriasis patients treated with any of the biological therapies
currently marketed in Hungary (adalimumab, etanercept, inflixi-
mab, ustekinumab), to compare long-term drug survival of such
therapies in the real-world settings and also to assess the impact
of additional factors, like patient age, gender, biological therapy-
naïve status or the use of methotrexate (MTX) on drug survival.
Methods
Patient enrollment
The data source for this retrospective analysis was the database of
the Hungarian National Health Insurance Fund (NHIF), which
ensured the comparative analysis of all relevant data collected in
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the real-world settings. NHIF’s database covers healthcare data of
the entire Hungarian population (nearly 10 million people) and
allows identifying all patients in Hungary with a record of any
reimbursed drug prescription and provides nonidentified patient
data on healthcare services and medical outcomes. Based on the
available data provided by NHIF, it was possible to analyze
patients’ age and gender, onset of disease, the collected data of
in- and outpatient care and previous therapies. As the NHIF data-
base includes PASI and DLQI scores of psoriasis patients only since
February 2012, PASI and DLQI scores were obtained from the
registries of participating university centers instead of the NHIF
database. In Hungary, patients suffering from psoriasis are eligible
for biologic treatment in case of severe disease (PASI 15 or
BSA 10 or DLQI 10) and documented intolerance or contraindi-
cation of standard systemic treatments. Hungarian Guideline on
Psoriasis Therapies is based on and synchronized with the
European S3 Psoriasis Guideline in accordance with the financing
protocol of the NHIF (13).
All psoriasis patients, who started at least one biological ther-
apy in Hungary, within the 46-months study period from 1 June
2010 to 1 April 2014, were enrolled in this study. Data of 1574
treatment episodes of 1263 patients were analyzed (since some
patients received more than one biological therapy over the study
period, the number of treatment episodes exceeded the number
of patients).
Treatment discontinuation was defined by the occurrence of
any of the following events: termination (no more prescription) or
reinduction of the biological therapy (at least 180 days pause of
biological therapy until the next prescription1) or switching to a
different biological therapy. There were several reasons of treat-
ment discontinuation; however, these kind of data were not cap-
tured in the NHIF registry. Since the authors have used the
database of the NHIF, no information was available on the reason
of therapy discontinuation. Data were censored for patients where
death of any cause occurred over the study period.
Statistical methods applied
Kaplan–Meier survival curve was used for the comparative analysis
of drug survival. Cox proportional hazard model was applied to
analyze the impact of patient age, gender, biological therapy-
naïve status and additional MTX therapy on drug survival. In order
to compare patients’ baseline characteristics, conservative WALD
test was used. ANOVA test, that is, two-factor variance analysis
was used to compare PASI and DLQI scores of treated patients as
these are continuous variables. Mean PASI and DLQI scores were
calculated using data collected from 641 patients treated by the
four university centers.
Results
Patients’ baseline characteristics
Data collected from a total number of 1263 patients were ana-
lyzed. Demographic data of patients are shown in Table 1.
Although the vast majority of the enrolled patients, (n¼ 972,
76.96%) received only one biological therapy over the study
period, 18.69% (n¼ 236) and 4.35% (n¼ 55) of the patients were
administered two and three or more biological therapies, respect-
ively. Since certain patients could have received several biological
therapies due to the therapeutic switches, the number of treat-
ment episodes (1574) exceeded the total patient number. All fur-
ther data will refer to treatment episodes.
Patients’ characteristics were also analyzed and compared
between subgroups receiving different biological therapies
(Table 2). The most frequently administered therapies were ada-
limumab and ustekinumab (n¼ 491 and n¼ 487, respectively),
followed by etanercept (n¼ 330), and infliximab (n¼ 266). The
analysis of each therapeutic groups showed that the distribu-
tion by gender, age and additional MTX usage was comparable
among the different therapeutic groups; however, the ratio of
biological therapy naïve patients was significantly different
between the infliximab and adalimumab groups as well as
between the ustekinumab and TNF-alpha inhibitors groups
(p< .05). Table 2 shows side-by-side comparison of data of
various treatment groups comparing patient age, gender, add-
itional MTX therapy and biological therapy naïve status.
Possible inhomogeneities in different treatment groups were
handled by using all of these four grouping variables as covari-
ates in the fitted Cox models; hence, the findings on drug sur-
vival analysis were not impacted by them. The comparison of
PASI (p¼ .18) and DLQI (p¼ .50) scores showed no significant
differences among the four subgroups using different biological
therapies.
Drug survival of biological therapies
The persistence was calculated by using the Kaplan–Meier
method and illustrated as a survival curve (Figure 1). The
results of the database analysis showed that the drug survival
rate of biological therapies in psoriasis patients is high as a
whole, since the overall survival rates are 79.70%, 68.52% and
60.75% in the first, second and third year of therapy,
respectively.
The cumulative data of the three TNF-alpha inhibitors showed
that drug survival probability was 73.28% in the first year, which
dropped to 60.22% in the second year to decrease as low as
50.76% in the third year.
Kaplan–Meier survival analysis of the individual TNF-alpha
inhibitors showed that drug survival of etanercept was 71.96% in
the first year, which dropped to 60.03% one year later to reach
49.49% after the third year. Drug survival of adalimumab and
infliximab was 68.98% and 70.92% in the first year, which dropped
to 58.13% and 49.79% one year later to reach 51.95% and 36.26%
after the third year, respectively. The comparison of the drug sur-
vival rates of the three TNF-alpha inhibitors showed that adalimu-
mab had the highest probability of patients staying on the
therapy for three consecutive years, although based on Cox model
results no significant difference among the three therapies could
be detected.
Drug survival rate of ustekinumab was 86.50% in the first year,
74.17% in the second year and 67.83% after the third year. The
comparison of drug survival rates of ustekinumab and TNF-alpha
inhibitors showed that the persistence of ustekinumab was signifi-
cantly higher if persistence was compared head-to-head with the
TNF-alpha inhibitors (p< .05), and this difference also persisted if
ustekinumab was compared to the cumulative data of the three
TNF-alpha inhibitors (p< .05).
Table 1. Characteristics of the study population.
Number of patients 1263
Mean age in years (SD) 49.3 (14.3)
Male/female (%) 61.3/38.7
Patients under 40 years/40 years or above (%) 29.3/70.7
Biological therapy naïve/previously treated (%) 81.3/18.7
Number of patients receiving MTX in addition
to the biological therapy
97
Mean PASI (SD) 20.5 (6.4)
Mean DLQI (SD) 20.0 (5.8)
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Predictors of biological survival
The Cox regression analysis of the impact of predictors, such as
patient age, gender, biological therapy naïve status and additional
MTX use on persistence, is shown in Figure 2. The analysis of all
biological therapies together revealed that the probability of stay-
ing on the therapy was significantly higher in male patients than
in female patients (p< .05, CI: 0.63, 0.92). Therapy-naïve status,
older age and the use of MTX all decreased the risk of dropping
out of therapy, although the impact was not significant (Figure 2).
The analysis of the cumulative data of all TNF-alpha inhibitor
therapies revealed that the impact of patient gender was signifi-
cant on drug survival: the risk of discontinuing the therapy was
0.71 times lower for male patients compared with female patients
(HR¼ 0.71, p< .05, CI: 0.58, 0.87).
The analysis of the individual therapy groups revealed the fol-
lowing: male gender had a favorable impact on the persistence of
adalimumab (HR¼ 0.73, p< .05 CI: 0.54, 0.99) and infliximab
(HR¼ 0.71, p< .05, CI: 0.49, 1) but did not influence the persist-
ence of etanercept. Patients over 40 years on etanercept showed a
significantly better persistence on the drug than patients younger
than 40 years of age (HR¼ 0.57, p< .05, CI: 0.4, 0.81). None of the
investigated predictors had a significant impact on drug survival
of ustekinumab.
Discussion
Suboptimal persistence was identified as a significant drawback in
the management of psoriatic patients, which considerably hinders
successful therapy, and can result in therapy discontinuation and
increased treatment costs (6,7,14). No conclusive findings have
been reached so far regarding the long-term drug survival rates of
biological therapies in psoriasis and predictors of their persistence.
Table 2. Baseline characteristics of patients receiving different biological therapies and pairwise comparison of the 4 groups regarding gender, age, ratio of bio-
logical naïve patients and MTX usage.
Therapy Adalimumab Etanercept Infliximab Ustekinumab
Treatment episodes (1574) 491 (31.2%) 330 (21.0%) 266 (16.8%) 487 (31.0%)
Mean age (SD) 47.24 (13.77) 47.55 (15.39) 49.92 (13.63) 47.71 (13.31)
Male/Female % 59.1%/40.9 56.4%/43.6 64.3%/35.7 61.4%/38.6
Patients under 40 years/40 years or above (%) 33.0/67.0 31.5/68.5 22.9/77.1 31.2/68.8
Biological therapy naïve/previously treated (%) 64.4/35.6 73.2/26.8 77.8/22.2 50.1/49.9
Patients receiving methotrexate in addition to the biological therapy (treatment episode) 40 16 26 32
p values of the conservative Wald tests, adjusted for the pairwise comparison of the proportion of gender
Adalimumab – 1 1 1
Etanercept 1 – 0.972 1
Infliximab 1 0.972 – 1
Ustekinumab 1 1 1 –
Age groups
Adalimumab – 1 0.192 1
Etanercept 1 – 0.385 1
Infliximab 0.192 0.385 – 0.385
Ustekinumab 1 1 0.385 –
Biological naïve patients
Adalimumab – 0.106 0.012 0.004
Etanercept 0.106 – 0.356 <0.001
Infliximab 0.012 0.356 – <0.001
Ustekinumab 0.004 <0.001 <0.001 –
Patients receiving MTX in addition to the biological therapy
Adalimumab – 0.85 1 1
Etanercept 0.85 – 0.6 1
Infliximab 1 0.6 – 1
Ustekinumab 1 1 1 –
Data are reported for treatment episodes.significant differences.
Figure 1. Kaplan–Meier survival curve of the four biologicals individually and in summary (all biological therapies). Data include 1574 treatment episodes. 491 adalimu-
mab treatment series, 330 etanercept series, 266 infliximab series and 487 ustekinumab series.
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This study is the first long-term study performed in Hungary on
the whole psoriatic patient population treated with biologicals, to
analyze the drug survival of all available biological therapies and
to investigate predictors of persistence in the real-life settings. A
further advantage of this study is that this is the first comprehen-
sive analysis on this topic in the literature using the database of
the NHIF of a given country.
The analysis of the present study population showed that ada-
limumab and ustekinumab were administered to almost equal
numbers of patients, while infliximab and etanercept were also
used in identical proportions, although less commonly than the
first two agents. Since all four biological therapies can be used
under the same circumstances in Hungary, the choice of drug
depended mostly on dermatologists’ preferences. The comparison
of the subgroups receiving different biological therapies revealed
that although there were certain differences among the four ther-
apy groups in terms of patients’ biological therapy-naïve status,
ultimately this factor did not prove to have statistically meaningful
effect on drug persistence rate or on predictor analysis, since the
statistical methods have addressed this issue. At the same time,
no significant differences were found in terms of PASI and DLQI
scores across the subgroups of patients on different biologicals.
The available literature has already shown that biological thera-
pies used in psoriasis have superior drug survival rates compared
to the rates seen with conventional systemic therapies (9).
Nevertheless, until recently, there was only a lack of data obtained
on large patient population treated for long time with TNF-alpha
inhibitors and IL-12/23 inhibitor in the real-life settings (11,15).
Table 3 summarizes all the studies published so far, where data
were collected from large patient population of two or more
centers, the follow-up period was at least one year, and the
authors compared at least three or more biological therapies. The
list includes five prospective registry-based studies and three
retrospective studies (5,11,16–20). Table 3 shows that those stud-
ies which included ustekinumab have found drug survival of uste-
kinumab superior to the drug survival of TNF-alpha inhibitors. The
largest study was published by Menter et al. analyzing data of
4000 patients taken from the PSOLAR registry, and their results
indicated that drug survival of ustekinumab was better than that
of TNF-inhibitors for both biological-naïve and biological-experi-
enced patients with psoriasis (20). This concurs with the results
from the British register (BADBIR) of 3523 bionaïve patients, where
the drug survival rate of ustekinumab has been found nearly 80%
at 3 years, which is significantly higher than that seen with TNF
inhibitors (17). Gniadecki et al. has also performed an updated
study involving 1277 psoriasis patients treated with biological
therapy and found that ustekinumab had the highest survival rate
(81.9%) at 4 years, followed by adalimumab and infliximab.
Between the TNF inhibitors, no significant differences were
detected (11). Our results are comparable to the above investiga-
tions and showed that drug survival rates of biologic therapies
were excellent compared to other therapies, even if they dimin-
ished over time: 79.70% after the first year, 68.52% after the
second year and 60% after the third year. At 3 years, drug survival
rates were 67.83% of ustekinumab, 51.95% of adalimumab,
49.49% of etanercept and 36.26% of infliximab. Our findings also
showed that drug survival of ustekinumab was superior to TNF-
alpha inhibitors and the significant difference persisted over the
3-year study period. Adalimumab was shown to have the highest
drug survival rate of all TNF- inhibitors studied; however, no
Figure 2. Predictors of biological survival. Multivariate analysis of predictors on biological therapies’ persistence rate (Cox proportional hazard and regression model).
The figure shows the risk of drop out of therapy by predictors such as patient age, gender, biological therapy naïve status and additional MTX usage. 1Reference cat-
egory: age 40. 2Reference category: female gender. 3Reference category: biological experienced patients. 4Reference category: patients who do not receive MTX.
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significant difference was found among these drugs over the
46months of the study period.
In addition to the analysis of persistence rates, it is also very
important to explore predictors of drug survival. No conclusive evi-
dence has yet been provided on the predictors of biological drug
survival in psoriasis. Studies done so far discussed the role of sev-
eral factors such as PASI, DLQI, comorbidities, age, gender, weight,
disease onset, duration of psoriasis, the presence of psoriatic arth-
ritis, concomitant MTX or biological therapy-naïve status and
smoking. In Table 4, we summarized results of long-term survival
analyses performed on large psoriasis patient populations, investi-
gating predictors of biological therapies only (11,16,18,20,21).
Three studies have shown that female gender is a predictor of dis-
continuation of biological therapies (11,18,20); however, Menter’s
data are not directly comparable with the aforementioned studies
since these authors analyzed biological naïve and experienced
patients’ predictors separately. On the other hand, other predictors
of discontinuation like previous treatment with biologics, smoking
status, higher DLQI, strict adherence to approved dose, the pres-
ence of comorbidities, were detected only in one of the aforemen-
tioned investigations (11,16,18,20,21).
In the present study, factors that could be extracted from the
database of the NFIH were investigated. In accordance with the
aforementioned authors, we could demonstrate the positive
Table 3. Studies on long-term drug survival of biological therapies in psoriasis.
Study Biologics
Patients/Treatment
periods
Follow-up
time (months) Best survival Source/regimen
R. Gniadecki et al. (2011) ADA, ETN, INF 747 patients/882
treatment episodes
48 INF (70%) DERMBIO; Danish prospective
registry
M. Esposito et al. (2013) ADA, ETN, INF 650 patients 28.9 ± 15.4 ETN (72.6%) Retrospective analysis from
three Italian referral
centers
van der Reek et al. (2014) ADA, ETN, UST 249 treatment
episodes
12 UST (85%) Bio-CAPTURE Dutch prospect-
ive registry
R.B. Warren et al. (2015) ADA, ETN, INF, UST 3523 patients 36 UST BADBIR registry; prospective
British cohort study
R. Gniadecki et al. (2015) ADA, ETN, INF, UST 1277 patients/1867
treatment episodes
followed for up
to 10 years
UST (81.9%
after 5 years)
DERMBIO Danish prospective
registry
E. Vilarrasa et al. (2016) ADA, ETN, INF, UST 427 patients/703
treatment episodes
48 UST Retrospective study, from
two Spanish center
A. Menter et al (2016) ADA, ETN, INF, UST 4000 patients 74 UST PSOLAR; prospective registry
from USA and European
countries
L. Pogacsas et al. (2016) ADA, ETN, INF, UST 1263 patients/1574
treatment episodes
46 UST 67.83% Retrospective study, database
of NHIF, Hungary
Data of those studies are summarized, which investigated persistence of at least three biologicals and were collected on large psoriasis patient population of two or
more centers and over long follow-up period (least one year). ADA: adalimumab; ETN: etanercept; IFN: infliximab; UST: ustekinumab.
Table 4. Studies on the predictors of biological therapies in psoriasis.
Study Biologics Examined predictors/covariates Significant covariates
R. Gniadecki et al. (2015) INF, ADA, ETN, UST 1277 patients/
1867 treatment episodes
Age, sex, previous biologic treatment,
weight, duration of psoriasis, presence
of PsA, baseline PASI and DLQI, con-
comitant MTX, number of
comorbidities
Predictors of discontinuation: female gen-
der; previous biologic treatment
R.B. Warren et al. (2015) INF, ADA, ETN, UST 3523 patients Age, sex, BMI, smoking status, presence
of PsA, number of comorbidities, dis-
ease duration, disease onset, PASI,
DLQI, unstable psoriasis, concomitant
MTX, concomitant cyclosporine
Predictors of discontinuation: female gen-
der, being current smoker, higher DLQI
Predictors of drug survival: presence of PsA
A. Menter et al. (2016) INF, ADA, ETN, UST 4000 patients Age, gender, ethnicity, BMI, familial psor-
iasis history, smoking status, alcohol
use status, duration of psoriasis, age at
the diagnosis of psoriasis, presence of
PsA, study site/geographic region, his-
tory of immunmodulator use, types of
insurance, previous biologic treatment,
reasons for discontinuation of prior
biologics, PSA, concomitant MTX use
Predictors of discontinuation: in bio naïve
patients: concomitant MTX, female gender
and geographic region (North America vs.
Latin America)
E. Vilarrasa et al. (2016) INF, ADA, ETN, UST 427 patients Sex, the presence of PsA, biologic naïve
status, use of combination treatment,
weight, strict adherence to approved
doses, PASI75 and PASI 90 response
Predictors of discontinuation obesity, strict
adherence to approved doses;
Predictors of drug survival: PASI75 and
PASI90 response at week 16
A. Jacobi et al. (2016) INF, ADA, ETN, UST, Efalizumab 125
treatment episodes
Biologic naïve status, presence of PsA,
and comorbidity with the presence of
metabolic syndrome
Predictors of discontinuation: comorbidities
Predictors of drug survival: the presence of
PsA
L. Pogacsas et al. (2016) INF, ADA, ETN, UST 1263 patients/
1574 treatment episodes
Gender, age, additional MTX therapy, bio-
logic naïve status
Predictors of discontinuation: female
gender
Data of those studies are summarized, which investigated predictors of at least three biologicals and were collected on large psoriasis patient population and over
long follow-up period (least one year).
ADA: adalimumab; DLQI: Dermatology Life Quality Index; ETN: etanercept; IFN: infliximab; MTX: methotrexate; PASI: psoriasis area severity index; PSA: physician’s glo-
bal assessment; UST: ustekinumab.
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impact of male gender on the persistence of infliximab and adali-
mumab, while it had no effect on the persistence of ustekinumab
and etanercept. It is not yet clear how gender impacts the persist-
ence of biological therapy in psoriasis, but remarkably, female
rheumatoid arthritis patients are also more likely to discontinue
therapy than males (22). Possible hypothetical explanations could
be that female patients may develop antidrug antibodies more
frequently resulting in decreased therapeutic efficacy, or alterna-
tively, psychological factors, such as dissatisfaction with treatment,
may play more important role in females, but until now compara-
tive studies were not performed.
In our study in the etanercept group, patients over 40 years
were more likely to stay on the therapy than their younger peers.
To our knowledge, no other previous investigations showed simi-
lar effect of age on the persistence of biological therapies.
In our study, biological-naive status and the use of MTX all
decreased the risk of dropping out of therapy, although the
impact was not significant. Biological therapy-naïve status was
shown to be a positive predictor for persistence in psoriasis by
Gniadecki et al., and, similarly, Lopez-Ferrer could also demon-
strate reduction of adalimumab drug survival in patients with
prior exposure to another TNF-alpha inhibitor. On the other hand,
there are studies which similar to the current study did not find
previous biological therapy usage as a negative predictor of per-
sistence (11,16,20,21,23). Although concomitant MTX usage has
been shown to be associated with a better persistence of biologi-
cals in rheumatological settings, there is no conclusive evidence
in psoriasis about additional MTX as a positive predictor (24,25). In
a systematic review, Bezooijen et al. selected eight studies, which
generally showed that combination therapy of biologicals and
MTX had higher efficacy than biological monotherapy, which
could also indicate a positive effect of MTX on the drug survival;
however, persistence was not investigated in this study (26). On
the other hand, Menter and colleagues unexpectedly reported
that patients receiving MTX were significantly more likely to dis-
continue biological treatment compared with those without con-
comitant MTX in bionaïve group, but not in biologic experienced
patients (20). Our present study did not show any significant
impact of the addition of MTX to the biological therapy on drug
survival rates of any of the biological drugs studied.
Based on the findings of this study drug survival rates of bio-
logic therapies can be regarded as excellent as the vast majority
of the patients (nearly 80%) received only one biological over the
3 years’ study period, and the mean survival rate did not diminish
below 60% even after 3 years. The IL-12/23 inhibitor ustekinumab
was shown to have significantly better drug survival rate than the
TNF-alpha inhibitors, and when analyzing consolidated data of all
assessed biologic therapies, male patients had better persistence
than female patients. One of the advantages of the present study
is that it is based on real-life data from the NHIF database, which
allowed to analyze the whole psoriatic patient population treated
with biological therapy in Hungary over a long period of time.
Limitations of the study
This is a retrospective analysis. Since the authors have used the
database of the NHIF, no information is available on the reason of
therapy discontinuation. It is also worthwhile mentioning that
while there is a patient support program for ustekinumab with
potential impact on drug survival rates, there is no information
available as to the existence of similar programmes for the TNF
inhibitors. An additional limitation of the study is that the NHIF
database did not include the PASI and DLQI scores of patients on
biological therapies, and, therefore, such data were taken from
the databases of the participant university centers, and, as such,
the data do not cover the full patient population.
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Note
1. Sensitivity analysis was carried out in order to identify the
most appropriate gap length for treatment discontinuation.
After a 180-day gap in the biological treatment, there were
only very limited number of patients who continued on the
same treatment with no other biological treatment in
between. These cases were considered as reinduction of
biological therapy.
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